|
1
|
Fearon K, Strasser F, Anker SD, Bosaeus I,
Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N,
Mantovani G, et al: Definition and classification of cancer
cachexia: An international consensus. Lancet Oncol. 12:489–495.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fearon KC: Cancer cachexia and fat-muscle
physiology. N Engl J Med. 365:565–567. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fearon KC, Glass DJ and Guttridge DC:
Cancer cachexia: Mediators, signaling, and metabolic pathways. Cell
Metab. 16:153–166. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Skipworth RJ, Stewart GD, Dejong CH,
Preston T and Fearon KC: Pathophysiology of cancer cachexia: Much
more than host-tumour interaction? Clin Nutr. 26:667–676. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tan BH, Birdsell LA, Martin L, Baracos VE
and Fearon KC: Sarcopenia in an overweight or obese patient is an
adverse prognostic factor in pancreatic cancer. Clin Cancer Res.
15:6973–6979. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Clark BC and Manini TM: What is dynapenia?
Nutrition. 28:495–503. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kushnir MM, Mrozinski P, Rockwood AL and
Crockett DK: A depletion strategy for improved detection of human
proteins from urine. J Biomol Tech. 20:101–108. 2009.PubMed/NCBI
|
|
8
|
Adachi J, Kumar C, Zhang Y, Olsen JV and
Mann M: The human urinary proteome contains more than 1500
proteins, including a large proportion of membrane proteins. Genome
Biol. 7:R802006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kalantari S, Jafari A, Moradpoor R,
Ghasemi E and Khalkhal E: Human Urine Proteomics: Analytical
techniques and clinical applications in renal diseases. Int J
Proteomics. 782798:2015.doi: 10.1155/2015/782798.
|
|
10
|
Caffrey RE: A review of experimental
design best practices for proteomics based biomarker discovery:
Focus on SELDI-TOF. Methods Mol Biol. 641:167–183. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wright GL Jr, Cazares LH, Leung SM, Nasim
S, Adam BL, Yip TT, Schellhammer PF, Gong L and Vlahou A:
Proteinchip(R) surface enhanced laser desorption/ionization (SELDI)
mass spectrometry: A novel protein biochip technology for detection
of prostate cancer biomarkers in complex protein mixtures. Prostate
Cancer Prostatic Dis. 2:264–276. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Husi H, Stephens N, Cronshaw A, MacDonald
A, Gallagher I, Greig C, Fearon KC and Ross JA: Proteomic analysis
of urinary upper gastrointestinal cancer markers. Proteomics Clin
Appl. 5:289–299. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Harridge SD, Kryger A and Stensgaard A:
Knee extensor strength, activation, and size in very elderly people
following strength training. Muscle Nerve. 22:831–839. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Todd G, Gorman RB and Gandevia SC:
Measurement and reproducibility of strength and voluntary
activation of lower-limb muscles. Muscle Nerve. 29:834–842. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Arden NK and Spector TD: Genetic
influences on muscle strength, lean body mass, and bone mineral
density: A twin study. J Bone Miner Res. 12:2076–2081. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Activity and Health Research: Allied
Dunbar National Fitness Survey: Main FindingsSummary. Health
Education Authority; London: 1992
|
|
17
|
Husi H, Skipworth RJE, Cronshaw A, Fearon
KCH and Ross JA: Proteomic identification of potential cancer
markers in human urine using subtractive analysis. Int J Oncol.
48:1921–1932. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Manini T and Clark B: Dynapenia and aging:
An update. J Gerontol A Biol Sci Med Sci. 67:28–40. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
O'Leary MF, Vainshtein A, Carter HN, Zhang
Y and Hood DA: Denervation-induced mitochondrial dysfunction and
autophagy in skeletal muscle of apoptosis-deficient animals. Am J
Physiol Cell Physiol. 303:C447–C454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bensalem N, Ventura AP, Vallée B, Lipecka
J, Tondelier D, Davezac N, Dos Santos A, Perretti M, Fajac A,
Sermet-Gaudelus I, et al: Down-regulation of the anti-inflammatory
protein annexin A1 in cystic fibrosis knock-out mice and patients.
Mol Cell Proteomics. 4:1591–1601. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Waddell LB, Lemckert FA, Zheng XF, Tran J,
Evesson FJ, Hawkes JM, Lek A, Street NE, Lin P, Clarke NF, et al:
Dysferlin, annexin A1, and mitsugumin 53 are upregulated in
muscular dystrophy and localize to longitudinal tubules of the
T-system with stretch. J Neuropathol Exp Neurol. 70:302–313. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gonzalez ML, Ruan X, Kumar P, Grammas P
and Pereira HA: Functional modulation of smooth muscle cells by the
inflammatory mediator CAP37. Microvasc Res. 67:168–181. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Koshy B, Matilla T, Burright EN, Merry DE,
Fischbeck KH, Orr HT and Zoghbi HY: Spinocerebellar ataxia type-1
and spinobulbar muscular atrophy gene products interact with
glyceraldehyde-3-phosphate dehydrogenase. Hum Mol Genet.
5:1311–1318. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guo DC, Papke CL, Tran-Fadulu V, Regalado
ES, Avidan N, Johnson RJ, Kim DH, Pannu H, Willing MC, Sparks E, et
al: Mutations in smooth muscle alpha-actin (ACTA2) cause coronary
artery disease, stroke, and Moyamoya disease, along with thoracic
aortic disease. Am J Hum Genet. 84:617–627. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu Z, Meyer-Hoffert U, Reithmayer K, Paus
R, Hansmann B, He Y, Bartels J, Gläser R, Harder J and Schröder JM:
Highly complex peptide aggregates of the S100 fused-type protein
hornerin are present in human skin. J Invest Dermatol.
129:1446–1458. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
St Swierzko A, Cedzynski M,
Domzalska-Popadiuk I, MacDonald SL, Borkowska-Klos M, Atkinson AP,
Szala A, Jopek A, Jensenius JC, Kawakami M, et al: Mannan-binding
lectin-associated serine protease-2 (MASP-2) in a large cohort of
neonates and its clinical associations. Mol Immunol. 46:1696–1701.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Schwaeble WJ, Lynch NJ, Clark JE, Marber
M, Samani NJ, Ali YM, Dudler T, Parent B, Lhotta K, Wallis R, et
al: Targeting of mannan-binding lectin-associated serine protease-2
confers protection from myocardial and gastrointestinal
ischemia/reperfusion injury. Proc Natl Acad Sci USA. 108:7523–7528.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Soltermann A, Ossola R, Kilgus-Hawelski S,
von Eckardstein A, Suter T, Aebersold R and Moch H: N-glycoprotein
profiling of lung adenocarcinoma pleural effusions by shotgun
proteomics. Cancer. 114:124–133. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Behrends C, Sowa ME, Gygi SP and Harper
JW: Network organization of the human autophagy system. Nature.
466:68–76. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hayashi T, Takeshita K, Tsuchida N, Kitano
K, Kawabata S, Iwanaga S and Ito T: Purification of a novel muscle
cell growth factor S-myotrophin from porcine skeletal muscle. Int J
Biochem Cell Biol. 30:897–908. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang X, Wang S, Tang X, Zhang A, Grabinski
T, Guo Z, Hudson E, Berghuis B, Webb C, Zhao P and Cao B:
Development and evaluation of monoclonal antibodies against
phosphatidylethanolamine binding protein 1 in pancreatic cancer
patients. J Immunol Methods. 362:151–160. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Notturno F, Capasso M, DeLauretis A, Carpo
M and Uncini A: Glial fibrillary acidic protein as a marker of
axonal damage in chronic neuropathies. Muscle Nerve. 40:50–54.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Husain H, Savage W, Grossman SA, Ye X,
Burger PC, Everett A, Bettegowda C, Diaz LA Jr, Blair C, Romans KE
and Holdhoff M: Pre- and post-operative plasma glial fibrillary
acidic protein levels in patients with newly diagnosed gliomas. J
Neurooncol. 109:123–127. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hui DY, Hayakawa K and Oizumi J:
Lipoamidase activity in normal and mutagenized pancreatic
cholesterol esterase (bile salt-stimulated lipase). Biochem J.
291:65–69. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kivirikko S, Saarela J, Myers JC,
Autio-Harmainen H and Pihlajaniemi T: Distribution of type XV
collagen transcripts in human tissue and their production by muscle
cells and fibroblasts. Am J Pathol. 147:1500–1509. 1995.PubMed/NCBI
|
|
36
|
Eklund L, Piuhola J, Komulainen J,
Sormunen R, Ongvarrasopone C, Fássler R, Muona A, Ilves M, Ruskoaho
H, Takala TE and Pihlajaniemi T: Lack of type XV collagen causes a
skeletal myopathy and cardiovascular defects in mice. Proc Natl
Acad Sci USA. 98:1194–1199. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mongiat M, Fu J, Oldershaw R, Greenhalgh
R, Gown AM and Iozzo RV: Perlecan protein core interacts with
extracellular matrix protein 1 (ECM1), a glycoprotein involved in
bone formation and angiogenesis. J Biol Chem. 278:17491–17499.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xu Z, Ichikawa N, Kosaki K, Yamada Y,
Sasaki T, Sakai LY, Kurosawa H, Hattori N and Arikawa-Hirasawa E:
Perlecan deficiency causes muscle hypertrophy, a decrease in
myostatin expression, and changes in muscle fiber composition.
Matrix Biol. 29:461–470. 2010. View Article : Google Scholar : PubMed/NCBI
|
